Boston Scientific Corporation BSX SPXR3KPHARMA
Company Overview
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Why Investors Should Care
Generates a return on equity of 15.3%, reflecting efficient use of shareholder capital.
Trades at a P/E of 19.4, below the sector median of 25.2.
Maintains a net profit margin of 17.5%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $20.07B (+19.9% YoY); net profit $2.90B.
- Trailing 12 Months Year-on-year growth — revenue +7.5%, earnings +15.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 5.3%, profit CAGR 9.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 5.29% |
| 1 Year: | 7.50% |
Compounded Profit Growth
| 5 Years: | 9.61% |
| 1 Year: | 15.10% |
Stock Price Performance
| 1 Year: | -53.37% |
| 6 Months: | -33.01% |
| 3 Months: | -1.54% |
| 1 Month: | -3.04% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)47.71 · Neutral
P/E of 19.35 is below the sector median of 25.17 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Trading 55.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BSX Boston Scientific Corporation SPXR3KPHARMA | 47.80 | 19.35 | $69.27B | 0.00% | 10.39% | 15.34% | 5.29% | 9.61% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 2.26B | 2.22B | 2.38B | 2.49B | 2.39B | 2.49B | 2.63B | 2.71B | 2.54B | 2.00B | 2.66B | 2.75B | 3.08B | 2.93B | 3.03B | 3.24B | 3.17B | 3.39B | 3.60B | 3.53B | 3.86B | 4.12B | 4.21B | 4.66B | 5.06B | 5.07B | 5.20B | 5.44B |
| Gross Profit | 1.28B | 1.23B | 1.24B | 1.31B | 1.30B | 1.25B | 1.30B | 1.35B | 1.39B | 1.49B | 1.51B | 1.51B | 1.62B | 1.58B | 1.71B | 1.75B | 1.72B | 1.76B | 1.87B | 1.93B | 1.74B | 1.21B | 1.79B | 1.86B | 2.13B | 2.03B | 2.07B | 2.23B | 2.19B | 2.35B | 2.54B | 2.43B | 2.65B | 2.85B | 2.90B | 3.21B | 3.42B | 3.54B | 3.61B | 3.85B |
| Operating Income | 220.00M | 103.00M | 197.00M | -69.00M | 64.00M | 24.00M | 219.00M | -299.00M | 293.00M | -334.00M | 348.00M | 364.00M | 225.00M | 377.00M | 407.00M | 392.00M | 388.00M | 541.00M | 384.00M | 383.00M | 146.00M | -71.00M | -205.00M | 370.00M | 262.00M | 387.00M | 466.00M | 423.00M | 358.00M | 552.00M | 514.00M | 693.00M | 675.00M | 520.00M | 733.00M | 921.00M | 819.00M | 1.05B | 1.10B | 1.18B |
| Diluted EPS | 0.10 | 0.00 | 0.10 | 0.00 | 0.03 | 0.00 | 0.08 | -0.15 | 0.15 | -0.15 | 0.17 | 0.21 | 0.11 | 0.20 | 0.21 | 0.40 | 0.31 | 0.30 | 0.11 | 0.09 | 0.01 | -0.11 | -0.12 | 0.23 | 0.12 | 0.28 | 0.07 | 0.17 | 0.12 | 0.21 | 0.18 | 0.34 | 0.33 | 0.22 | 0.32 | 0.45 | 0.53 | 0.51 | 0.90 | 0.61 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.36B | 8.05B | 8.19B | 7.81B | 7.62B | 6.96B | 7.07B | 7.46B | 8.07B | 8.39B | 9.05B | 9.82B | 10.73B | 9.91B | - | 12.68B | 14.24B | 16.75B | 20.07B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.96B | 4.34B | 5.26B | 6.22B |
| Gross Profit | 6.01B | 5.58B | 5.61B | 5.21B | 4.96B | 4.90B | 4.97B | 5.17B | 5.30B | 5.96B | 6.46B | 7.01B | 7.62B | 6.45B | - | 8.73B | 9.89B | 11.49B | 13.85B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.69B | 7.48B | 8.49B | 9.88B |
| Operating Income | -14.00M | -1.50B | -894.00M | -656.00M | 904.00M | -3.87B | 120.00M | -301.00M | -283.00M | 447.00M | 1.28B | 1.51B | 1.52B | -80.00M | - | 2.03B | 2.42B | 3.00B | 3.97B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.75B | 3.45B | 3.86B | 5.10B |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 470.00M | 265.00M | 305.00M | 349.00M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.14B | 1.99B | 2.28B | 3.38B |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 443.00M | 393.00M | 436.00M | 493.00M |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | 1.67B | 4.70B | -115.00M | - | 698.00M | 1.59B | 1.85B | 2.90B |
| Diluted EPS | -0.33 | -1.36 | -0.68 | -0.70 | 0.29 | -2.89 | -0.09 | -0.09 | -0.18 | 0.25 | 0.08 | 1.19 | 3.33 | -0.08 | - | 0.45 | 1.07 | 1.25 | 1.94 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 27.14B | 25.18B | 22.13B | 21.29B | 17.15B | 16.57B | 17.02B | 18.13B | 18.10B | 19.04B | 21.00B | 30.57B | 30.78B | 32.23B | 32.47B | 35.14B | 39.40B | 43.67B |
| Total Equity | - | - | 13.17B | 12.30B | 11.30B | 11.35B | 6.87B | 6.54B | 6.46B | 6.32B | 6.73B | 7.01B | 8.73B | 13.88B | 15.33B | 16.62B | 17.57B | 19.28B | 21.77B | 24.23B |
| Cash & Equivalents | 1.67B | 1.45B | 1.64B | 864.00M | 213.00M | 267.00M | 207.00M | 217.00M | 587.00M | 319.00M | 196.00M | 188.00M | 146.00M | 217.00M | 1.73B | 1.93B | 928.00M | 865.00M | 414.00M | 1.97B |
| Long Term Debt | - | - | - | - | 5.45B | 4.20B | 4.20B | 4.20B | 4.20B | 5.65B | 5.42B | 3.81B | - | - | - | - | - | - | - | - |
| Current Liabilities | - | - | 3.23B | 3.02B | 2.61B | 1.81B | 1.77B | 1.82B | 2.85B | 2.43B | 3.59B | 5.65B | 5.26B | 4.87B | 3.68B | 4.27B | 3.80B | 4.93B | 6.40B | 5.44B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 934.00M | 1.22B | 835.00M | 325.00M | 1.01B | 1.28B | 1.11B | 1.27B | 691.00M | 1.18B | 1.43B | 310.00M | 1.84B | 1.51B | 1.87B | 1.53B | 2.50B | 3.44B | 4.53B |
| Investing Cash Flow | -474.00M | 324.00M | -793.00M | -468.00M | 776.00M | -579.00M | -475.00M | -745.00M | -2.19B | -887.00M | -1.01B | -1.92B | -5.04B | -411.00M | -1.60B | -2.01B | -2.57B | -5.69B | -2.64B |
| Financing Cash Flow | -680.00M | -1.35B | -820.00M | -508.00M | -1.73B | -764.00M | -624.00M | -150.00M | 1.28B | -206.00M | 110.00M | 1.43B | 2.97B | 293.00M | -95.00M | -548.00M | 5.00M | 1.81B | -395.00M |
| Capital Expenditure | -363.00M | -362.00M | -312.00M | -272.00M | -304.00M | -226.00M | -245.00M | -259.00M | -247.00M | -376.00M | -319.00M | -316.00M | -461.00M | -376.00M | -554.00M | -588.00M | -711.00M | -790.00M | -876.00M |
| Free Cash Flow | 571.00M | 854.00M | 523.00M | 53.00M | 704.00M | 1.05B | 865.00M | 1.01B | 444.00M | 806.00M | 1.11B | -6.00M | 1.38B | 1.13B | 1.32B | 938.00M | 1.79B | 2.65B | 3.66B |
| Share Buybacks | - | - | - | - | 492.00M | 600.00M | 500.00M | 125.00M | 0 | 0 | - | 0 | 0 | 535.00M | 0 | 0 | - | - | - |
| Dividends Paid | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 28.00M | 55.00M | 55.00M | 28.00M | 0 | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 72.0% | 69.3% | 68.5% | 66.7% | 65.1% | 70.4% | 70.3% | 69.3% | 65.7% | 71.1% | 71.3% | 71.4% | 71.0% | 65.0% | - | 68.8% | 69.5% | 68.6% | 69.0% |
| Operating Margin % | -0.2% | -18.7% | -10.9% | -8.4% | 11.9% | -55.6% | 1.7% | -4.0% | -3.5% | 5.3% | 14.2% | 15.3% | 14.1% | -0.8% | - | 16.0% | 17.0% | 17.9% | 19.8% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | 17.0% | 43.8% | -1.2% | - | 5.5% | 11.2% | 11.1% | 14.4% |
| ROE % | - | - | - | - | - | - | - | - | - | - | - | 19.1% | 33.9% | -0.8% | - | 4.0% | 8.3% | 8.5% | 12.0% |
| ROCE % | - | -6.3% | -4.0% | -3.4% | 4.6% | -25.1% | 0.8% | -2.1% | -1.8% | 3.1% | 9.6% | 9.6% | 5.9% | -0.3% | - | 7.1% | 8.0% | 9.1% | 10.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.95% | 129.68M | $6.07B |
| 2 | Vanguard Capital Management LLC | 6.70% | 97.09M | $4.55B |
| 3 | State Street Corporation | 4.84% | 70.11M | $3.28B |
| 4 | Primecap Management Company | 3.49% | 50.52M | $2.37B |
| 5 | FMR, LLC | 3.15% | 45.70M | $2.14B |
| 6 | Geode Capital Management, LLC | 2.31% | 33.44M | $1.57B |
| 7 | Vanguard Portfolio Management LLC | 2.06% | 29.79M | $1.40B |
| 8 | Shaw D.E. & Co., Inc. | 1.76% | 25.46M | $1.19B |
| 9 | Massachusetts Financial Services Co. | 1.72% | 24.86M | $1.16B |
| 10 | JPMORGAN CHASE & CO | 1.65% | 23.91M | $1.12B |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BSX
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPYmk1cHpVaS15YVM4T3ozMmV6azdDdGdjeWdhLWZHNjBDTnNHMVA3TU5sWkt6Y0htaWVTQ3ZPV1FEcVpUbXdBbk9EOElvZUNHQnU5cW1RdHlKSzdpTFpXZ2dySURPQmxUYUVGTW1jRTFiV2duWEY0UEFaSHhTeGtsS2tBR3VCYkZlS2hNY3…
BSX Stock Picks Up Steam After $2B Buyback, $1.5B Investment By Company – But Here’s Why BofA Slashed Its Price Target - Stocktwits
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPVnpmM3BDbFVuc3pMYWF4YXlJR0VWT1E0b1p0ZnJSRlhIaWM5TjFoSTZVSUVqNWZ6dkI0SGwtdDBHOGdNRkFoWVpmZFpfakVObXVyWG5GQzluTkc2YTRJaVlXLTB2YWlMcjRqWXE3RG1BMm1kaERjeTFXZ0IyVTBNcUFURjg3aXJMaTFPYT…
How Much Upside Can BSX Stock’s Growth Deliver? - Trefis
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxONC0wd3NuWXkydWFuOVAwSFZheHVSYUR4TXk4N0hESDdYeDdHMFcyaGFheGtYQlFaTFJ3VWJoLUVKU1JFTFdBWUk2OGJpWlNBRjBqTWxxTFB5UVNNRV9uZDE4ZVBHWTM4WVRscGstdVlDbzl5VVhhOE5nRG1naVZwZXpielA3cHdKZS1BTU…
Boston Scientific (BSX) Stock Looks Cheap On Cash Flow While Earnings Face Doubts - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxONVd1T1NObmwwRmdDek9uMTJhSDU1bFNKMy1vdkxqa0J0bFVMempKV0s4bl9GUV9YV2NMT251MXVGdl9abTlmal9CdmpvQmw2Vi1ZTS1JVEl3ZGRKUlVhNjN2UU5tRmlVVWR5MzcybkROckozVWY2SzJZcjVscnBGVTluSDBuRktiQWYxWE…
$BSX stock rose 2% this week. Here's what we see in our data. - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPVjROMl8zMUdIUm8yMmVheWlrNlhlUFhteWNiX0pJdE9pOU1PR0pIcmQ1ZWtfWHF0aGpvQ3NNcmhXVktLWW8yd3ZKS1FZamU1UkxDSUl0OVlGMGc1N3lDbmxReE5NV0JaemQ1emx1ME42Q0xPeVhtVzRyVEpPaHVSMFZ6aUdYLTF4UHJtN1…
Boston Scientific Hammered On Cybersecurity Attack - Investor's Business Daily
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxQcGI5VTkwTndMOHdHVFJSTGN3NkVHemEzc2EyRW9rU3llaUxxZXBRTTA2aFItY3VmX0w0ZXlkazc1d1pRNk5HV2JYdHNTYjVPb0RYWFdLY2o1cXo1by13bzd3cXE2REU0VEV4LS1PNUNpallTcVBzTi1YOGt5WVZZeDRKMjBrbWpxNlNBck…
BSX — Frequently Asked Questions
What is the current share price of Boston Scientific Corporation (BSX)?
As of 2026-09-07 16:24 PDT, Boston Scientific Corporation (BSX) trades at $47.80 on NYSE. Its 52-week range is $42.63 to $108.14.
What is the market capitalisation of BSX?
Boston Scientific Corporation (BSX) has a market capitalisation of $69.27B on NYSE.
What is the P/E ratio of BSX?
BSX trades at a trailing price-to-earnings (P/E) ratio of 19.35. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.86.
What is the return on equity (ROE) of BSX?
BSX has a return on equity (ROE) of 15.34%. Its return on capital employed (ROCE) is 10.39%.
Is BSX a good stock to buy?
This page provides a data-driven analysis of Boston Scientific Corporation (BSX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.